← Leaderboards
Ann Mullally
Brigham And Women'S Hospital
$5,507,634
Attributed
$6,588,239
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,588,239 · 3
By mechanism
R01$5,902,199 · 2
K08$686,040 · 1
Top collaborators
- Seung Ha Nam4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Kellie Rae Machlus$5,242,384
- Shannon Elisabeth Elf$2,739,617
- Kenneth M Kaye$21,944,697
- Andrew P Weng$900,720
- Lynn Bry$10,918,358
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoHematopoieticMolecularCellsJak2 GeneHematopoietic Stem CellsHematological DiseaseMutantMutationMouse ModelMyeloproliferative DiseaseGenesHematopoiesisNovel Therapeutic InterventionPathway InteractionsPhenotypeMutateMediatingInsightBlood CellsDissectionInnovationProductionInhibitor/Antagonist
Grant awards (18)
Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells$700,999
R01 · FY2025 · HL
Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells - Diversity Supplement$54,859
R01 · FY2025 · HL
Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells$686,979
R01 · FY2024 · HL
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$355,000
R01 · FY2024 · HL · contact PI
Elucidating Mechanisms of Therapy-Resistance to Interferon-alfa in Myeloproliferative Neoplasm Stem Cells$718,374
R01 · FY2023 · HL
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$401,996
R01 · FY2023 · HL · contact PI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$401,996
R01 · FY2022 · HL · contact PI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$401,996
R01 · FY2021 · HL · contact PI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$436,000
R01 · FY2020 · HL · contact PI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$436,000
R01 · FY2019 · HL · contact PI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$436,000
R01 · FY2018 · HL · contact PI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$436,000
R01 · FY2017 · HL · contact PI
Functional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative Neoplasms$436,000
R01 · FY2016 · HL · contact PI
Functional and Molecular Dissection of Myeloproliferative Neoplasm Stem Cells$137,370
K08 · FY2015 · HL · contact PI
Functional and Molecular Dissection of Myeloproliferative Neoplasm Stem Cells$137,370
K08 · FY2014 · HL · contact PI
Functional and Molecular Dissection of Myeloproliferative Neoplasm Stem Cells$137,370
K08 · FY2013 · HL · contact PI
Functional and Molecular Dissection of Myeloproliferative Neoplasm Stem Cells$137,370
K08 · FY2012 · HL · contact PI
Functional and Molecular Dissection of Myeloproliferative Neoplasm Stem Cells$136,560
K08 · FY2011 · HL · contact PI